BIXT BIOXYTRAN, INC revenue, earnings and financials
For the quarter ended June 30, 2026, BIOXYTRAN, INC reported revenue of n/a, net income of −$620K and diluted EPS of −$0.01; for the fiscal year ended December 2025 revenue was n/a.
BIXT annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$1.84M, net income −$2.12M (margin n/a), EPS −$0.02
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$2.22M, net income −$2.37M (margin n/a), EPS −$0.02
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$3.80M, net income −$4.47M (margin n/a), EPS −$0.03
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$2.44M, net income −$2.47M (margin n/a), EPS −$0.02
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$4.21M, net income −$4.03M (margin n/a), EPS −$0.04
BIXT quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$620K, EPS −$0.01
- Quarter ended Mar 31, 2026: revenue n/a, net income −$2.07M, EPS −$0.02
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$522K, EPS $0.00
- Quarter ended Sep 30, 2025: revenue n/a, net income −$283K, EPS $0.00
- Quarter ended Jun 30, 2025: revenue n/a, net income $35.4K, EPS $0.00
- Quarter ended Mar 31, 2025: revenue n/a, net income −$1.35M, EPS −$0.02
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$752K, EPS −$0.02
- Quarter ended Sep 30, 2024: revenue n/a, net income −$392K, EPS $0.00
- Quarter ended Jun 30, 2024: revenue n/a, net income −$662K, EPS $0.00
- Quarter ended Mar 31, 2024: revenue n/a, net income −$561K, EPS $0.00
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$1.15M, EPS $0.00
- Quarter ended Sep 30, 2023: revenue n/a, net income −$1.09M, EPS −$0.01
- Quarter ended Jun 30, 2023: revenue n/a, net income −$1.45M, EPS −$0.01
- Quarter ended Mar 31, 2023: revenue n/a, net income −$785K, EPS −$0.01
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$815K, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$124K, EPS $0.00
- Quarter ended Jun 30, 2022: revenue n/a, net income −$622K, EPS −$0.01
- Quarter ended Mar 31, 2022: revenue n/a, net income −$912K, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$1.04M, EPS −$0.01
- Quarter ended Sep 30, 2021: revenue n/a, net income −$475K, EPS $0.00
BIXT cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$526K, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$381K, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$775K, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$1.80M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$1.70M, share buybacks n/a
BIXT balance sheet
- Jun 30, 2026: cash n/a, total assets $333K, total liabilities $5.27M, shareholders' equity −$4.94M
- Mar 31, 2026: cash n/a, total assets $615K, total liabilities $5.01M, shareholders' equity −$4.39M
- Dec 31, 2025: cash n/a, total assets $659K, total liabilities $3.25M, shareholders' equity −$2.59M
- Sep 30, 2025: cash n/a, total assets $156K, total liabilities $3.06M, shareholders' equity n/a
- Jun 30, 2025: cash n/a, total assets $148K, total liabilities $2.78M, shareholders' equity −$2.64M
- Mar 31, 2025: cash n/a, total assets $136K, total liabilities $2.84M, shareholders' equity −$2.71M
- Dec 31, 2024: cash n/a, total assets $139K, total liabilities $1.93M, shareholders' equity −$1.79M
- Sep 30, 2024: cash n/a, total assets $159K, total liabilities $1.24M, shareholders' equity n/a
Is BIXT profitable?
No. BIOXYTRAN, INC lost $3.49M over the last four quarters.
What is BIXT's EPS?
Diluted earnings per share over the last four quarters were −$0.03; −$0.01 in the latest quarter.